FGFR1 and gastric adenocarcinoma: Compared with FGFR1 non-amplified gastric adenocarcinoma, FGFR1-amplified cases are associated with poor 10-year survival (p = 0.047) and a higher rate of distant metastasis (p = 0.025) (Schafer et al., 2015).